Sanofi, a global healthcare company, completed the acquisition of TZIELD royalty interest from DRI Capital-backed DRI Healthcare Trust, a global pharmaceutical royalty monetization company, for $210m. “DRI Healthcare is excited about the dramatic positive impact that TZIELD™ will have on patients who are at risk of developing Type 1 Diabetes. This is only the second time in 21 years that we have sold a royalty to a third party. Having only recently announced the TZIELD™ royalty acquisition, DRI Healthcare was not looking to sell the royalty,” Behzad Khosrowshahi, DRI Healthcare Trust CEO.